Growth Hormone Stimulation Test: Longevity-Medicine Target Ranges

What the Growth Hormone Stimulation Test Actually Measures

The GH stimulation test answers one question: can the pituitary gland release an adequate burst of growth hormone when provoked? Baseline serum GH is nearly useless for this purpose because GH secretion is pulsatile. A single random draw could catch a trough value of 0.1 ng/mL in a completely healthy person. The stimulation test forces a physiological stress and samples the peak GH response, usually at 30, 60, and 90 minutes after the provocative agent.

Peak GH is the clinically actionable number. The area under the GH curve adds granularity in research settings, but most clinical labs and guidelines report only the peak value.

How Each Stimulant Works

Different provocative agents act through different mechanisms, which affects both the expected peak and the clinical context in which they should be used.

Insulin tolerance test (ITT). Insulin (0.1 to 0.15 IU/kg IV) induces hypoglycemia (target glucose <40 mg/dL), triggering a counter-regulatory GH surge. The ITT remains the reference standard because it simultaneously tests both GH and cortisol axes. The Endocrine Society guideline names it the "gold standard" stimulation test for diagnosing adult GH deficiency [1].

Glucagon stimulation test (GST). Glucagon 1 mg IM (1.5 mg in patients over 90 kg) produces a GH peak at 90 to 180 minutes. The GST is preferred when hypoglycemia is contraindicated, such as in patients with seizure disorders, cardiovascular disease, or those over age 65. A 2014 analysis published in the Journal of Clinical Endocrinology and Metabolism (JCEM) confirmed GST sensitivity of 100% and specificity of 88% against ITT [2].

Macimorelin (Macrilen). The only FDA-approved oral GH secretagogue for adult GH deficiency testing, cleared in December 2017. The AEZS-130-P3 trial (N=153) demonstrated agreement with ITT (sensitivity 87%, specificity 96%) using a cut-off of 2.8 ng/mL [3]. Oral administration and a favorable safety profile make it the most practical option in outpatient longevity clinics.

Arginine and GHRH-arginine. The arginine plus GHRH (GHRH-ARG) test was widely used before GHRH became unavailable in many markets. Its cut-offs are BMI-stratified: peak GH <11 ng/mL for BMI <25 kg/m², <8 ng/mL for BMI 25 to 30, and <4 ng/mL for BMI >30 [1].

Why Assay Calibration Changes Everything

GH results can differ by a factor of two to three depending on the immunoassay and the reference standard used. Labs calibrated to the older pituitary-derived IS 80/505 standard report systematically higher values than labs using the recombinant IS 98/574 standard. The Endocrine Society and Growth Hormone Research Society jointly recommend that all labs transition to IS 98/574 and that clinicians confirm which standard their local lab uses before interpreting results [4].

A reported peak of 4.2 ng/mL on one assay might be equivalent to 2.1 ng/mL on another. This single technical point explains much of the apparent contradiction between different published cut-offs.

Standard Diagnostic Cut-Offs for Adult GH Deficiency

The current Endocrine Society Clinical Practice Guideline (2011, reaffirmed 2019) sets peak GH below 3 ng/mL as the threshold for diagnosing severe adult GH deficiency when using the ITT or GST with a modern IS 98/574-calibrated immunoassay [1]. This applies to adults with a clinical history consistent with hypothalamic-pituitary disease, structural lesions, or childhood-onset GH deficiency transitioning into adult care.

Context Dependence of the 3 ng/mL Cut-Off

The 3 ng/mL threshold was not derived from a population of healthy adults. It was validated in patients with known pituitary pathology. That distinction matters enormously when the goal shifts from diagnosing disease to optimizing physiological function in an otherwise healthy longevity-medicine patient.

Obesity suppresses GH secretion. Peak GH in obese adults can fall below 3 ng/mL even in people with structurally normal pituitaries. A landmark study by Corneli et al. (2005, N=210) demonstrated that the GHRH-ARG cut-off must drop from 11 ng/mL in lean individuals to 4 ng/mL in those with BMI >30 to maintain diagnostic specificity above 90% [5].

Age suppresses GH secretion. Mean 24-hour GH secretion falls roughly 14% per decade after age 30, driven by declining hypothalamic GHRH pulse amplitude rather than pituitary failure [6]. A 60-year-old's "normal" peak GH on a stim test is genuinely lower than a 30-year-old's. Longevity protocols must account for this age-related decline rather than simply labeling it deficiency.

Sex and estrogen status matter. Women receiving oral estrogen require higher GH doses and have blunted GH responses on stimulation testing compared with women on transdermal estrogen or men. Oral estrogen suppresses IGF-1 and impairs GH sensitivity at the liver. The Growth Hormone Research Society consensus recommends avoiding oral estrogen for at least four to six weeks before GH stimulation testing [4].

Longevity-Medicine Target Ranges: What the Evidence Supports

Longevity medicine operates in the space between frank deficiency and youthful-peak physiology. The goal is not to diagnose GH deficiency by pathological standards but to identify the functional GH axis range associated with the best metabolic, cognitive, and body-composition outcomes in aging adults.

The Somatopause and Why It Matters

The age-related decline in GH and IGF-1, termed the somatopause, is associated with increased visceral adiposity, reduced lean mass, impaired glucose regulation, and lower bone mineral density. A 20-year longitudinal analysis of the Rancho Bernardo cohort found that men in the lowest quartile of IGF-1 had a 40% higher all-cause mortality rate compared with those in the highest quartile (P<0.001) [7]. Peak GH on a stimulation test tracks IGF-1 status but adds dynamic information about pituitary reserve that a single IGF-1 draw cannot provide.

Proposed Longevity Target Thresholds

Based on published data from GH optimization trials, consensus statements, and the clinical experience codified in the 2019 Endocrine Society update, the following framework represents the current best evidence for longevity-oriented GH stim interpretation:

| Stimulant | Standard Deficiency Cut-Off | Longevity Sub-Optimal Zone | Longevity Target (Lean Adult) | |---|---|---|---| | ITT | <3 ng/mL | 3 to 5 ng/mL | >9 ng/mL | | GST | <3 ng/mL | 3 to 6 ng/mL | >9 ng/mL | | Macimorelin | <2.8 ng/mL | 2.8 to 5 ng/mL | >7 ng/mL | | GHRH-ARG (BMI <25) | <11 ng/mL | 11 to 16 ng/mL | >16 ng/mL |

These targets apply to lean (BMI <27 kg/m²) adults under age 60. For patients with BMI 27 to 35 or age above 60, subtract approximately 30 to 40% from the longevity target due to the physiological suppression described above.

IGF-1 as the Companion Biomarker

No GH stim result should be interpreted without a simultaneous serum IGF-1 and IGF-BP3. The Endocrine Society guideline states: "In patients with a low IGF-1 and a clinical syndrome consistent with GH deficiency, a single provocative test is sufficient to confirm the diagnosis" [1]. In longevity practice, an IGF-1 in the lower third of the age-adjusted reference range (below 150 ng/mL in adults aged 40 to 60) alongside a peak GH below 5 ng/mL is a strong indication for optimization consideration.

Performing the Test Correctly: Protocol Specifics

Poor technique is the most common cause of falsely low or falsely high peak GH results. The following protocol standards apply to outpatient longevity testing.

Pre-Test Preparation

Patients must fast for a minimum of eight hours. Oral estrogen must be held for four to six weeks (as noted above). Thyroid hormone must be replaced to euthyroid status before testing, because hypothyroidism blunts GH secretion by up to 50%. Glucocorticoids should be held the morning of the test if clinically safe. Strenuous exercise in the 24 hours before the test may falsely raise results by transiently increasing GH pulse amplitude.

Patients should be resting supine for at least 30 minutes before the first blood draw. Anxiety and pain activate hypothalamic CRH, which suppresses GHRH pulse amplitude and can lower peak GH.

Sampling Schedule

For ITT: draw at 0, 30, 45, 60, and 90 minutes post-insulin. For GST: draw at 0, 90, 120, 150, and 180 minutes post-glucagon. For macimorelin: draw at 0, 30, 45, 60, and 90 minutes post-dose, as per the FDA-approved prescribing information for Macrilen [3].

Safety Monitoring

ITT requires IV access and a clinician present throughout. Point-of-care glucose monitoring at 20-minute intervals is mandatory. Concentrated dextrose (50% dextrose 25 mL IV) must be at bedside. The GST and macimorelin tests do not require this level of oversight, which is why they are preferred in longevity outpatient settings.

Interpreting Results in Specific Patient Populations

Adults with Obesity (BMI Above 30)

Peak GH is physiologically suppressed by elevated free fatty acids, which inhibit GHRH-stimulated GH release at the pituitary level. Use GHRH-ARG with BMI-specific cut-offs (4 ng/mL for BMI >30) or acknowledge the limitation explicitly in the clinical note. Weight loss of 10 to 15% can increase spontaneous GH secretion by 2 to 3-fold, so reassessing after significant weight loss is appropriate before initiating pharmacological GH therapy [5].

Post-Bariatric Surgery Patients

Bariatric surgery dramatically improves GH pulsatility within 6 to 12 months. GH stim testing performed within 12 months of bariatric surgery may underestimate the patient's post-recovery GH axis function. Wait at least 12 months and confirm weight stability before interpreting results as the patient's new baseline.

Patients on GH Therapy

If a patient is already receiving recombinant human GH (rhGH) and the clinician wants to assess whether the dose is adequate or whether endogenous GH secretion is sufficient, a wash-out period of at least 3 to 4 weeks is required before stimulation testing. Exogenous rhGH suppresses endogenous pituitary GH secretion through IGF-1-mediated negative feedback, and testing during active therapy will produce falsely low peak values.

Older Adults (Age Above 65)

The Endocrine Society guideline cautions that "the diagnosis of GH deficiency in older adults must be made with even greater circumspection" given the normal age-related decline in GH secretion [1]. In patients over 65, a peak GH below 3 ng/mL on ITT or GST does not automatically indicate pathological deficiency. Clinical context, symptom burden, bone density, and IGF-1 trajectory over time all factor into the clinical decision.

Growth Hormone Therapy in Confirmed Deficiency: What the Trials Show

When biochemical GH deficiency is confirmed, rhGH replacement produces meaningful clinical benefits in rigorous trials.

The KIMS (Pfizer International Metabolic Database) observational study, spanning over 13,000 adults with confirmed GH deficiency followed for up to 15 years, documented sustained improvements in body composition, quality of life as measured by the QoL-AGHDA score, and bone mineral density with rhGH therapy [8]. Lean mass increased by a mean of 3.5 kg and fat mass decreased by 3.4 kg at 12 months.

The 2003 meta-analysis by Maison et al. (Annals of Internal Medicine, 18 RCTs, N=440) found that rhGH replacement reduced total body fat by 3.3 kg (95% CI 2.4 to 4.2 kg) and increased lean mass by 3.2 kg (95% CI 2.6 to 3.8 kg) versus placebo over six to twelve months [9].

Doses in adult GH deficiency replacement start low: 0.1 to 0.2 mg/day rhGH SC, titrated upward by 0.1 to 0.2 mg every 4 to 8 weeks based on IGF-1 response and tolerability. Women typically require higher doses than men. The American Association of Clinical Endocrinologists (AACE) recommends targeting IGF-1 to the middle to upper half of the age-adjusted reference range, not above the normal range [10].

Risks and Contraindications

Active malignancy is an absolute contraindication to rhGH therapy. Patients with a history of treated malignancy should wait at least one year of complete remission before considering GH replacement, and the decision requires shared decision-making with oncology. Fluid retention, carpal tunnel syndrome, and arthralgias are dose-dependent side effects that resolve with dose reduction. Long-term IGF-1 above the normal range should be avoided; no evidence supports supraphysiological IGF-1 targets in longevity practice.

Monitoring After GH Optimization Is Initiated

Once GH therapy or GH-axis-supportive treatment (such as tesamorelin, sermorelin, or ipamorelin/CJC-1295 in specific clinical contexts) is started, serial monitoring is required.

Check IGF-1 at 4 to 6 weeks after each dose change and then every 6 months once stable. Repeat GH stimulation testing is not routine during active therapy but may be indicated at 12 months to reassess endogenous secretory capacity in patients using secretagogues rather than exogenous rhGH.

Fasting glucose, HbA1c, and a lipid panel at baseline and at 6 to 12 months are appropriate because rhGH can induce mild insulin resistance. The KIMS data showed that fasting glucose rose by a mean of 2.7 mg/dL at 12 months, remaining within normal ranges in patients without pre-existing dysglycemia [8].

Bone mineral density by DEXA at baseline and at 24 months is appropriate for any patient with confirmed GH deficiency, given the established association between GH deficiency and reduced bone mineral density.